Paradigm Capital Management Inc. NY Acquires 901,600 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Paradigm Capital Management Inc. NY raised its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 170.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,431,100 shares of the life sciences company's stock after purchasing an additional 901,600 shares during the quarter. Integra LifeSciences makes up 1.5% of Paradigm Capital Management Inc. NY's holdings, making the stock its 21st biggest position. Paradigm Capital Management Inc. NY owned about 1.85% of Integra LifeSciences worth $32,457,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in IART. Soleus Capital Management L.P. acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $28,940,000. Lord Abbett & CO. LLC boosted its position in shares of Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock valued at $30,210,000 after acquiring an additional 618,773 shares during the period. Norges Bank acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at about $8,967,000. Systematic Financial Management LP increased its position in Integra LifeSciences by 40.7% during the fourth quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company's stock worth $19,518,000 after acquiring an additional 248,817 shares during the period. Finally, Access Investment Management LLC bought a new position in Integra LifeSciences during the fourth quarter worth about $4,416,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Price Performance

Shares of IART stock traded down $0.36 on Friday, hitting $12.30. 989,046 shares of the company's stock were exchanged, compared to its average volume of 1,043,354. The company has a 50 day moving average of $17.03 and a 200 day moving average of $21.34. The stock has a market cap of $955.86 million, a P/E ratio of -136.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 12 month low of $11.60 and a 12 month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the previous year, the business posted $0.55 earnings per share. The company's revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

IART has been the topic of a number of analyst reports. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. JPMorgan Chase & Co. lowered their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.